Design, Synthesis and Biological Activity of New Amides Derived from 3‐Benzhydryl and 3‐ sec ‐Butyl‐2,5‐dioxo‐pyrrolidin‐1‐yl‐acetic Acid

The aim of this study was to design and synthesize two new series of pyrrolidine‐2,5‐dione‐acetamides with a benzhydryl or sec ‐butyl group at position 3 as potential anticonvulsants. Their anticonvulsant activity was evaluated in standard animal models of epilepsy: the maximal electroshock (MES), the 6 Hz, and the subcutaneous pentylenetetrazole ( sc PTZ) tests. The in vivo studies revealed the most potent anticonvulsant activity for 15 (3‐( sec ‐butyl)‐1‐(2‐(4‐(3‐trifluoromethylphenyl)piperazin‐1‐yl)‐2‐oxoethyl)pyrrolidine‐2,5‐dione), with ED 50 values of 80.38 mg/kg (MES) and 108.80 mg/kg (6 Hz). The plausible mechanism of action was assessed in in vitro binding assays, in which 15 interacted effectively with voltage‐gated sodium (site 2) and L‐type calcium channels at a concentration of 100 μM. Subsequently, the antinociceptive activity of compounds 7 and 15 was observed in the hot plate test of acute pain. Moreover, compounds 7 , 11 and 15 demonstrated an analgesic effect in the formalin test of tonic pain. The hepatotoxic properties of the most effective compounds ( 7 , 11 and 15 ) in HepG2 cells were also investigated.